Background: Mast cells (MCs) are hematopoietic cells that mature in tissues and are involved in allergy, immunity, and inflammation by secreting multiple mediators. The natural flavone luteolin has anti-inflammatory actions and inhibits human mast cells (MCs).

Objective: We sought to investigate the ability of luteolin and its novel structural analog 3′,4′,5,7-tetramethoxyluteolin (methlut) to inhibit human MC mediator expression and release in vitro and in vivo.

Methods: Human LAD2 cells and umbilical primary human cord blood–derived cultured mast cells were stimulated with substance P (SP) or IgE/anti-IgE and then challenged intradermally. Methlut was also studied in mice passively sensitized with dinitrophenol–human serum albumin and challenged intradermally.

Results: Methlut is a more potent inhibitor than luteolin or cromolyn for de novo–synthesized TNF from LAD2 cells and of CCL2 from human cord blood–derived cultured MCs. This mechanism of action for methlut might be due to its ability to inhibit intracellular calcium level increases, as well as nuclear factor κB induction, at both the transcriptional and translational levels in LAD2 cells stimulated by SP without affecting cell viability. Intraperitoneal treatment with methlut significantly decreases skin vascular permeability of Evans blue dye in mice passively sensitized to dinitrophenol–human serum albumin and challenged intradermally.

Conclusion: Methlut is a promising MC inhibitor for the treatment of allergic and inflammatory conditions. (J Allergy Clin Immunol 2015;135:1044-52.)

Key words: Allergy, inflammation, mast cells, luteolin, tetramethoxyluteolin, calcium, nuclear factor κB

Mast cells (MCs) are immune cells derived from hematopoietic precursors that mature in tissue microenvironments. In addition to allergic triggers, MCs can be stimulated by neuropeptides, such as substance P (SP). On stimulation, MCs release preformed mediators stored in their numerous secretory granules; these include β-hexosaminidase, histamine, TNF, and tryptase through rapid degranulation, as well as newly synthesized prostaglandin D2 (PGD2), TNF, and CCL2 (monocyte chemoattractant protein 1).

MC-derived histamine induces bronchoconstriction and mucus secretion, contributing to asthma. MCs are probably the only cell type that stores preformed TNF, which is rapidly released and influences T-cell recruitment and activation. MC-derived CCL2 and CXCL-8 (IL-8) enhance recruitment of immune cells to the site of inflammation. The ability to release multiple mediators allows MCs to actively interact with other cell types in their surrounding environment and participate in the induction, propagation, or both of various immune and inflammatory responses, including mastocytosis, asthma, atopic dermatitis, and psoriasis. Therefore inhibition of MC activation has clear therapeutic potential.

Disodium cromoglycate (cromolyn; Fig 1, A) is the only clinically available MC stabilizer because it was reported to reduce gastrointestinal effects in patients with mastocytosis. Even though cromolyn inhibits rat peritoneal MC histamine secretion, it does not inhibit rat mucosal MCs or mouse MCs. A recent study concluded that the beneficial effect of cromolyn in reducing pruritus in human subjects might be mediated through inhibition of sensory nerve endings instead of MCs. In addition, poor intestinal absorption of cromolyn severely limits its clinical efficacy. Consequently, there is an urgent need to develop effective inhibitors of human MCs.

While searching for potential MC inhibitors, we noticed that part of the structure of cromolyn is similar to the backbone of flavones (see Fig E1, highlighted areas, in this article’s Online Repository at www.jacionline.org), which are naturally occurring compounds with potent antioxidant, anti-inflammatory, and MC-blocking activities. The flavone luteolin (see Fig E1) inhibits the release of histamine and PGD2 from human cultured MCs. Luteolin also inhibits mercury-induced vascular endothelial growth factor release from human MCs and activated T cells. The structural analog of luteolin, 3′,4′,5,7-tetramethoxyluteolin (methlut; see Fig E1) is more lipid soluble than luteolin, more likely to penetrate cells, and less metabolized. However, the action of methlut on MC activation has not been investigated.
In this study we examined whether methlut could inhibit mediator release from human cultured MCs stimulated by an allergic or a neuropeptide trigger and compared it with luteolin and cromolyn. We also studied the effect of methlut in mice passively sensitized to dinitrophenol-human serum albumin (DNP-HSA) and challenged intradermally.

**METHODS**

**Reagents**

Recombinant human stem cell factor (rhSCF) was kindly donated by Orphan Biovitrum AB (Stockholm, Sweden). Cromolyn, luteolin, and SP were purchased from Sigma-Aldrich (St Louis, Mo). Methlut was obtained from Orphan Biovitrum AB (Stockholm, Sweden). Cynomolyn, luteolin, and methlut were dissolved in dimethyl sulfoxide (DMSO). SP was prepared in distilled water. Working dilutions for all compounds were prepared in culture medium immediately before use. The final concentration of DMSO was less than 0.1% and had no effect on cell viability.

**Human MC culture**

The limited number of MCs obtained from normal human tissues has led to the increased use of human LAD2 cells derived from a human patient with MC leukemia or primary human cord blood-derived MCs (hCBMCs). Human LAD2 cells (kindly supplied by Dr A. Kirshenbaum, National Institutes of Health, Bethesda, Md) were cultured in StemPro-34 medium (Life Technologies, Carlsbad, Calif) supplemented with 2 mmol/L of D-glucosamine and had no effect on cell viability. LAD2 cells (0.5 × 10⁵) were preincubated with cromolyn, luteolin, or methlut immediately before use. The final concentration of DMSO was less than 0.1% and had no effect on cell viability.

**RNA isolation and quantitative real-time PCR**

LAD2 cells and hCBMCs (5 × 10⁵) were treated with luteolin or methlut (10-100 μmol/L for 30 minutes) before stimulation with SP (2 μmol/L for 30 minutes). LAD2 cells were treated with cromolyn (100 μmol/L) and SP (2 μmol/L) at the same time to test the effect of cromolyn. Control cells were treated with 0.1% DMSO. Supernatant fluids were collected, and cell pellets were lysed with 1% Triton X-100. Supernatants and cell lysates were incubated in the reaction buffer (p-nitrophenyl-N-acetyl-β-D-glucosaminide from Sigma) for 1.5 hours, and then 0.2 mol/L glycine was added to stop the reaction. Absorbance was measured at 405 nm. Results are expressed as the percentage of β-hexosaminidase released over the total amount present in LAD2 cells.

MC degranulation was also assessed by measuring histamine release. After the same treatment, LAD2 cells were pretreated with cromolyn, luteolin, or methlut and subsequently stimulated with SP. Supernatant fluids were collected, and histamine release was measured with a Histamine EIA Kit (Cayman Chemical, Ann Arbor, Mich).

**TNF and CCL2 ELISA**

For TNF release, LAD2 cells (1 × 10⁵) were preincubated with cromolyn, luteolin, or methlut (10-100 μmol/L) and subsequently stimulated with SP (2 μmol/L) for 30 minutes to measure preformed TNF release. LAD2 cells were also stimulated for 24 hours to measure de novo-synthesized TNF release, which occurs in addition to rapid preformed TNF release. TNF levels were measured in supernatant fluids by using a TNF ELISA assay kit (R&D Systems, Minneapolis, Minn).

For CCL2 release, primary hCBMCs (1 × 10⁵) were primed with human IgE (1 μg/mL; Millipore, Billerica, Mass) overnight and preincubated with cromolyn, luteolin, or methlut (50 μmol/L) for 30 minutes before stimulation with anti-IgE (10 μg/mL for 2 hours, Life technologies). CCL2 was measured with a CCL2 ELISA assay kit (R&D Systems).

**Intracellular calcium measurements**

LAD2 cells were incubated in Tyrode buffer with the calcium indicator Fura-2 AM (30 μmol/L for 20 minutes, Life Technologies). Cells were washed and resuspended in plain Tyrode buffer and incubated for another 20 minutes. Cells were then transferred to 96-well plates (1 × 10⁵ cells per well) and pretreated with luteolin or methlut (10 and 50 μmol/L for 20 minutes) before stimulation with SP (2 μmol/L). Changes in Fura-2 AM fluorescence was immediately read with the MDC FlexStation II (Molecular Devices, Sunnyvale, Calif) at an excitation wavelength of 340 nm/380 nm and an emission wavelength of 510 nm. Results were processed according to the Life Technologies Fura-2 AM protocol and reported as the relative ratio.
NF-κB inhibitor α phosphorylation assay

The nuclear transcription factor NF-κB plays a pivotal role in the regulation of inflammatory mediator expression. On stimulation, the NF-κB inhibitor α (IκBα) is rapidly phosphorylated and degraded, allowing NF-κB to translocate into the nucleus, where it binds to the promoter region of a number of target genes. We investigated the effects of luteolin and methlut on IκBα phosphorylation and NF-κB DNA-binding activity, as described later. After preincubation with either luteolin or methlut (10 or 50 μmol/L for 30 minutes), LAD2 cells (4 × 10⁶) were stimulated with SP (2 μmol/L for 15 minutes). Phosphorylation of IκBα (serine 32) was detected by using the PathScan NF-κB p65 in the extracts was detected by using specific primary antibody directed against NF-κB followed by horseradish peroxidase (HRP)- conjugated secondary antibody to provide a colorimetric readout at 450 nm. Relative NF-κB p65 DNA-binding activities in the cytosolic and nuclear extracts were normalized to values in control cells treated with 0.1% DMSO.

NF-κB DNA-binding activity

After luteolin and methlut preincubation (10 and 50 μmol/L for 30 minutes), LAD2 cells (4 × 10⁶) were stimulated with SP (2 μmol/L for 15 minutes). Cells were harvested, and cytosolic and nuclear extracts were isolated by using an NE-PER nuclear extraction kit (Thermo Scientific, Rockford, Ill). DNA-binding activity of NF-κB p65 in the extracts was detected by using the NF-κB (p65) Transcription Factor Assay Kit (#10007889; Cayman Chemical). Cytosolic and nuclear extracts (each containing 10 μg of protein) were added to 96-well plates coated with a specific double-stranded DNA sequence containing the NF-κB response element. NF-κB was detected by addition of specific primary antibody directed against NF-κB followed by horseradish peroxidase (HRP)- conjugated secondary antibody to provide a colorimetric readout at 450 nm. Relative NF-κB p65 DNA-binding activities in the cytosolic and nuclear extracts were normalized to values in control cells treated with 0.1% DMSO.

Intracellular ATP measurement

Intracellular ATP content was measured to determine whether luteolin and methlut have any effect on cellular energy production. After incubation with luteolin or methlut (10-100 μmol/L for 24 hours), 1 × 10⁶ LAD2 cells were lysed, and intracellular ATP contents were determined by using an ATP assay kit (Abcam, Cambridge, Mass).

Cell viability

Cell viability was assayed by means of trypan blue exclusion. The effect of luteolin and methlut (100 μmol/L) was tested on LAD2 cells, hCBMCs, and microglial cells and was greater than 98% viable after 24 hours of incubation. Luteolin was recently reported not to affect the viability of HaCaT keratinocytes and primary cultured keratinocytes.

Evans blue extravasation

Evans blue extravasation was performed, as previously described. Passive cutaneous anaphylaxis was produced as follows: normal saline or anti-DNP IgE (20 μg/50 μL, Sigma) was administered intradermally at 2 skin sites on each mouse (n = 5). Two days later, dinitrophenol–human serum albumin (DNP-HSA) (200 μg) along with 1% Evans blue in sterile normal saline (100 μL) was injected into the tail vein. Male BALB/c mice (6-8 weeks old; Charles River, Wilmington, Mass) were then anesthetized by means of an intraperitoneal injection (0.1 mL) of ketamine (100 mg/kg)/xylazine (10 mg/kg), after which the dorsal subscapular skin was shaved and either 10 μg of SP or DNP-HSA (200 μg) was injected intradermally in a total volume of 50 μL in the subscapular region with a tuberculin syringe. Mice were pretreated with an intraperitoneal injection of normal saline or methlut (100 mg/kg) 30 minutes before the intradermal injections. Mice were killed, and the skin was removed, turned over, and photographed. Circular pieces of skin at each injection site (8 mm diameter) were removed with a puncher, weighted, and placed in Eppendorf tubes. Evans blue was extracted in 1 mL of N,N-dimethylformamide overnight at 55°C, and the OD was measured at 620 nm with a PerkinElmer Luminescence Spectrophotometer (PerkinElmer, Norwalk, Conn). The Evans blue concentration was calculated by using a standard curve, and values were normalized to tissue weight. Intravascular Evans blue and nonspecific effects of injection were accounted for by subtracting the Evans blue extracted after injection of normal saline.

Statistical analysis

All experiments were performed in triplicate and repeated at least 3 times (n = 3). Results are presented as means ± SDs. Data between different treatment groups were analyzed by using the unpaired 2-tailed Student t test.

RESULTS

Methlut inhibits SP-stimulated LAD2 cell degranulation

SP (2 μmol/L for 30 minutes) triggers significant release of β-hexosaminidase (Fig 1, A) and preformed TNF (Fig 1, B) from LAD2 cells. Luteolin and methlut inhibit β-hexosaminidase release by 74% and 85%, respectively (Fig 1, A). Cromolyn reduces β-hexosaminidase release (Fig 1, A) but does not reduce TNF release (Fig 1, B), whereas luteolin and methlut significantly inhibit both β-hexosaminidase and TNF release by more than 70% (Fig 1). The inhibitory effect of methlut is greater than that of luteolin. Cromolyn reduces SP-stimulated β-hexosaminidase release by 30% (Fig 1, A), but it must be added together with the trigger because preincubation for 30 minutes eliminates its inhibitory activity (see Fig E3 in this article’s Online Repository at www.jacionline.org). Instead, luteolin and methlut inhibit β-hexosaminidase release whether added together or 30 minutes before the trigger (Fig 1, A).

The inhibitory effect of the flavonoids is dose dependent (10-100 μmol/L for 30 minutes), with almost complete inhibition...
of SP-stimulated β-hexosaminidase, histamine, and preformed TNF release at 100 μmol/L (Fig 2, B).

**Methlut inhibits IgE/anti-IgE–stimulated β-hexosaminidase and TNF release from LAD2 cells**

We also stimulated LAD2 cells with IgE/anti-IgE. Preincubation with luteolin or methlut (100 μmol/L for 30 minutes) significantly inhibits IgE/anti-IgE–stimulated β-hexosaminidase release by 70% and 99%, respectively (Fig 3, A). Similar inhibition is seen for the release of preformed TNF (Fig 3, B).

**Methlut inhibits SP-stimulated de novo TNF synthesis and release from LAD2 cells**

In addition to preformed TNF, MCs also release newly synthesized TNF 12 to 24 hours later. SP (2 μmol/L for 24 hours) triggers significant TNF release (Fig 4, A and B), which is dose-dependently inhibited by preincubation with luteolin or methlut (1-100 μmol/L for 30 minutes). Prolonged preincubation times do not increase the extent of inhibition, except for luteolin, where inhibition at 10 μmol/L becomes more prominent after 12 and 24 hours compared with 30 minutes (Fig 4, A). Methlut is more effective than luteolin at 10 μmol/L. Moreover, luteolin at 50 μmol/L reduces TNF release by about 50%, whereas methlut achieves 95% inhibition at the same concentration (Fig 4, B). Cromolyn has no inhibitory effect (results not shown).

Preincubation with luteolin or methlut for 30 minutes also significantly decreases TNF mRNA expression (Fig 4, C and D). Methlut, even at 10 μmol/L, is more effective than luteolin and reduces SP-stimulated TNF expression by 73% (Fig 4, D). Cromolyn has no effect (results not shown).

**Methlut inhibits IgE/anti-IgE–stimulated CCL2 synthesis and release from IgE/anti-IgE–stimulated hCBMCs**

We investigated the effect of the flavonoids on release of CCL2 because CCL2 is known to be synthesized by MCs and stimulates recruitment of immune cells to the site of inflammation.

Stimulation of hCBMCs with IgE/anti-IgE (10 μg/mL for 24 hours) triggers CCL2 release from primary hCBMCs. This effect is blocked by preincubation with luteolin or methlut (10 or 50 μmol/L for 30 minutes; Fig 5, A). Anti-IgE stimulation (10 μg/mL for 6 hours) also triggers a 2-fold increase in CCL2 mRNA expression compared with that seen in control cells primed with IgE only (Fig 5, B); this effect is also completely inhibited by preincubation with luteolin or methlut (50 μmol/L for 30 minutes) but not by cromolyn (results not shown).

**Methlut inhibits NF-κB activation**

In LAD2 cells SP (2 μmol/L for 15 minutes) rapidly causes IκBα phosphorylation on serine 32 (Fig 6, A), which allows subsequent activation of NF-κB. Preincubation with luteolin or methlut (10 or 50 μmol/L for 6 hours) dose-dependently decreases IκBα phosphorylation compared with that seen in control cells (Fig 6, A). In addition, preincubation with luteolin or methlut (10 or 50 μmol/L for 6 hours) significantly decreases the DNA-binding activity of NF-κB p65 in the nuclear extract (Fig 6, B). The DNA-binding activity of NF-κB p65 in the cytosolic extract is not affected (data not shown). At 10 μmol/L, methlut is more effective than luteolin in reducing both IκBα phosphorylation and DNA-binding activity of NF-κB p65 in the nucleus.

**Methlut inhibits mRNA expression of NF-κB–related genes**

NFκB1 encodes for the NF-κB p50 subunit, and RELA encodes for the NF-κB p65 subunit. In LAD2 cells SP (2 μmol/L for 6 hours) slightly induces mRNA expression levels of NFκB1 (Fig 7, A) and RELA (Fig 7, B), which are decreased by preincubation (10-100 μmol/L for 30 minutes) with luteolin or methlut. Methlut is more effective than luteolin. Similar results are obtained in primary hCBMCs, where preincubation with methlut (50 μmol/L for 30 minutes) significantly decreases mRNA expression levels of both NFκB1 (Fig 7, C) and RELA (Fig 7, D). Preincubation with luteolin (50 μmol/L for 30 minutes) only slightly reduces the mRNA expression of NFκB1 and RELA, but this reduction is not statistically significant.

**Methlut inhibits intracellular calcium increase**

SP (2 μmol/L) triggers a rapid intracellular calcium increase in LAD2 cells (see Fig E4 in this article’s Online Repository at www.jacionline.org). Preincubation with luteolin (50 μmol/L for 30 minutes) inhibits calcium increase by 50%. Preincubation (100 μmol/L for 30 minutes) triggers a rapid increase of calcium release.
with methlut (50 μmol/L for 30 minutes) completely blocks calcium increase, which is even lower than in control cells treated with DMSO (see Fig E4).

**Methlut does not alter intracellular ATP production**

Neither luteolin nor methlut (100 μmol/L) reduces cell viability (results not shown). To further document the lack of any detrimental effect on cellular function, we examined the effects of luteolin and methlut on intracellular ATP production. Preincubation with luteolin or methlut (100 μmol/L for 24 hours) decreases intracellular ATP content by 10% and 15%, respectively (see Fig E5 in this article’s Online Repository at www.jacionline.org), which is not statistically significant.

**Methlut prevents increased vascular permeability caused by either SP or DNP-HSA**

Intradermal injection of SP (10 μmol/L) or DNP-HSA in mice passively sensitized to HSA significantly increases Evans blue skin extravasation (Fig 8, A). Mice injected intraperitoneally with methlut (100 mg/kg for 30 minutes) before intradermal injection have significantly reduced vascular permeability to either SP or DNP-HSA (Fig 8, B).

**DISCUSSION**

Our results indicate that the novel flavone methlut is more potent than luteolin and significantly inhibits human LAD2 cell release of histamine, β-hexosaminidase, and preformed TNF. In contrast, an equimolar concentration of cromolyn, the only compound marketed as an MC stabilizer, reduces β-hexosaminidase release by about 30%, but not preformed TNF release, when LAD2 cells are stimulated by SP. In addition, both luteolin and methlut are effective when administered before the trigger, whereas cromolyn has to be added together with the trigger for any inhibition to be evident because of rapid tachyphylaxis. We also previously showed that the flavonol quercetin, which is structurally related
to luteolin, is more effective than cromolyn in blocking hCBMC cytokine release. Nevertheless, cromolyn (100 μmol/L) inhibited histamine release from hCBMCs by about 60%, PGD<sub>2</sub> release by 80%, and LTC<sub>4</sub> by 100%. A recent publication also reported that cromolyn inhibited PGD<sub>2</sub> release from hCBMCs stimulated by IgE/anti-IgE by 100%. Therefore it is apparent that cromolyn can inhibit the release of histamine and arachidonic acid products, but not cytokines, either due to IgE/anti-IgE or SP stimulation. In contrast, luteolin and methlut are more effective MC inhibitors than cromolyn, regardless of the trigger and the mediator measured. Moreover, luteolin and methlut were effective when MCs were preincubated, whereas cromolyn had to be added together with the trigger for its inhibition to manifest. Further incubation with luteolin up to 48 hours does not reduce TNF gene expression any more than what we observe at 24 hours (results not shown). There is no evidence the flavonoids are metabolized inside the cells. The inhibitory effect of methlut also remains the same up to 48 hours (results not shown).

We also report that both luteolin and methlut inhibit the release of CCL2 from hCBMCs. Although luteolin had been reported to inhibit histamine release from hCBMCs, this is the first time that luteolin and methlut have been reported to inhibit CCL2 release. CCL2 is known to be synthesized by MCs and stimulates recruitment of immune cells to the site of inflammation.

We also examined several key signaling processes involved in MC activation, including intracellular calcium and ATP production and activation of the nuclear transcriptional factor NF-κB. Here we show that methlut inhibits the inducible transcription factor NF-κB, which is a protein complex that translocates from the cytoplasm into the nucleus on activation and regulates gene expression of various inflammatory mediators. Methlut prevents phosphorylation of IκBα, which is an upstream inhibitor of NF-κB and is degraded on phosphorylation.

We also show that methlut decreases NF-κB p65 DNA-binding activity in the nuclear extract. Apart from inhibiting NF-κB activation at the protein level, we also report, for the first time to our knowledge, that methlut decreases mRNA expression of 2 genes encoding different subunits in the NF-κB protein complex: NFKB1 (encoding NF-κB p50 subunit) and RELA (encoding NF-κB p65 subunit). By blocking NF-κB activation at both the gene and protein levels, methlut and luteolin can effectively regulate proinflammatory mediator production. Luteolin had been reported to inhibit cytokine production by blocking NF-κB in leukemic HMC-1 cells. However, HMC-1 cells do not express the high-affinity FcεRI receptor for IgE, and they proliferate independently of stem cell factor, which is absolutely required for proliferation of primary human MCs. In our studies we used the LAD2 cell line, which is a more mature human MC line than HMC-1, with functional FcεRI and dependence on stem cell factor.

Lut and methlut effectively block stimulated intracellular calcium increase, which is required for MC degranulation.
Because methlut has 4 methoxyl groups substituted for the 4 hydroxyl groups on luteolin (Fig 1, C and D), the calcium-blocking action of luteolin is unlikely to be due to any polyphenolic structure, where calcium chelation can occur. These flavones might also inhibit or activate the regulatory components of calcium signaling pathways in MCs. For instance, luteolin-7-O-glucoside inhibited phospholipase C phosphorylation in mouse MCs50 and the structurally related flavonol quercetin blocked calcium-dependant protein kinase C.51 This effect on stimulated calcium increase should not be of concern for cardiac cells and neurons because the calcium spikes in these cell types are voltage gate regulated, whereas the calcium increase in MCs is not.52 In fact, luteolin did not have any effect on calcium ion levels in neonatal cultured cardiomyocytes (results not shown).53

We were obviously interested in knowing whether the flavones tested affect cell viability and whether any such effect might be mediated through reduction in cellular ATP levels. Neither flavone significantly reduced the viability of human MCs. Moreover, luteolin does not affect the viability of T cells,32 keratinocytes,59 or microglia54 for up to 24 hours. Both luteolin and methlut had no significant effect on intracellular ATP content in MCs.

Here we also show that methlut inhibits skin vascular permeability stimulated by intradermal SP and DNP-HSA in passively sensitized mice. This method was previously used to document the effect of other inhibitors on MC activation,40 as well as of resveratrol on passive cutaneous anaphylaxis in mice.55 Moreover, the flavonoid concentrations used here in this mouse model (100 mg/kg) have already been shown to have a statistically significant benefit, at least for luteolin, in children with autism,56 many of whom have been reported to have “allergic-like” symptoms57 implicating MC activation.58

Surprisingly, we show that methlut is more effective than luteolin in decreasing MC activation. The substitution of the 4
hydroxy groups in luteolin by methoxyl groups (Fig 1, D) apparently enhances the inhibitory activity (Fig 1, C). This finding seems to contradict previous studies that showed flavones containing more hydroxy groups have greater antiasthma effects.59 However, additional publications support the present findings. For instance, 6-methoxyluteolin significantly inhibits histamine and intracellular calcium increase in human cultured basophilic KU812F cells.60 Two polymethoxy flavones (3′,4′,5,6,7,8-hexamethoxy flavone [nobiletin] and [4′,5,6,7,8-pentamethoxy flavone] tangeretin) prevent LPS-induced bone loss in a mouse model of periodontitis and inhibit PGE2 production in cocultures of bone marrow cells and osteoblasts.61

Another possible explanation might be that the presence of the methyl groups in methlut permits greater penetration in MCs and higher intracellular concentration than luteolin. In addition, methoxy flavones are less metabolized, thereby increasing their biological activities,33 an important attribute because flavonoids are extensively metabolized.32

Luteolin apparently does not have any cell selectivity for MCs because it had previously been shown to also inhibit stimulation of human T cells54 and keratinocytes,53 as well as microglia.63 However, our preliminary evidence (unpublished) indicates that both methlut and luteolin are preferentially taken up by immune cells, especially those with phagocytic activity, such as MCs, macrophages, and microglia. A potential mechanism of selectivity of flavonoids, where luteolin was the best inhibitor of histamine and β-hexosaminidase release, might be disruption of distinct MC vesicle secretion by interacting with granule-dependent SNARE complexes.64 Interestingly, the beneficial action of cromolyn might also not be selective for MCs because it could be mediated through inhibition of sensory nerve endings, as recently shown for a cromolyn-containing skin cream.26 Other studies have shown that cromolyn might stimulate afferent nerves in human subjects.26

Our present results indicate that the natural flavone methlut is a potent inhibitor of human MC inflammatory mediator release. Its likely mechanism or mechanisms of action involve decreasing intracellular calcium levels and decreasing NF-κB activation at both the transcriptional and translational levels. Methlut has the potential to be developed into a promising MC blocker for the treatment of allergic and inflammatory conditions in which MC activation is involved, particularly when made into formulations that increase its solubility and absorption.

We thank Dr A. S. Kirshenbaum (National Institutes of Health) for providing the LAD2 human MCs and Swedish Orphan Biovitrum AB for their generous gift of rhSCF. We also thank Dr Errol (Department of Obstetrics and Gynecology, Tufts Medical Center) for providing the umbilical cord blood.

**Key messages**

- Methlut inhibits release of inflammatory mediators from human MCs stimulated by allergic and neuropeptide triggers.
- Methlut is more effective than luteolin and cromolyn for inhibition of MCs.
- Methlut inhibits skin vascular permeability in a passively sensitized mouse model.

**REFERENCES**

FIG E1. Structures are shown for cromolyn (A), flavone backbone (B), luteolin (C), and methlut (D).
FIG E2. Purity of methlut. Analysis was done by means of mass spectrometry, as detailed in the Methods section.
FIG E3. Cromolyn (Crom) loses its inhibitory effect on LAD2 cell degranulation if used as pretreatment. MCs were preincubated with cromolyn (100 μmol/L) for 30 minutes before stimulation with either SP (2 μmol/L) or anti-IgE (10 μg/mL) for an additional 30 minutes. A, β-Hexosaminidase release. B, Histamine release. *ns, No statistical significance.*
FIG E4. Methlut and luteolin (Lut) inhibit intracellular calcium level increase. LAD2 cells were loaded with Fura-2 AM (30 nmol/L for 20 minutes) and then preincubated with luteolin or methlut (10 and 50 μmol/L for 30 minutes). Immediately after stimulation with SP (2 μmol/L), Fura-2 AM fluorescence was monitored at an excitation wavelength of 340 nm and 380 nm and an emission wavelength of 510 nm. Control cells were treated with 0.1% DMSO. The curve shown is representative of 5 experiments with similar results.
FIG E5. Luteolin and methlut do not affect intracellular ATP levels. After incubation with luteolin (A) or methlut (B; 10-100 μmol/L up to 24 h), 1 × 10^6 LAD2 cells were lysed, and intracellular ATP contents were determined.